Home

Jason Aryeh

CIK 1376960 · last filed 2026-06-25

Jason Aryeh is a corporate insider who has filed 177 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for OBIO, was dated Jun 25, 2026. Across all open-market trades the lifetime net is −$34.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $50.4M across reported positions. 77 SEC filings were submitted jointly with LIGAND PHARMACEUTICALS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$50.41M

Companies

11

Total Filings

177

Lifetime Open-Market Net

-$34.25M

Filer Profile

Reported Address
11119 NORTH TORREY PINES ROAD
SUITE 200
LA JOLLA, CA 92037
Related Filers
LIGAND PHARMACEUTICALS INC — 77 joint filings, latest 2026-06-12
QLT INC/BC — 22 joint filings, latest 2017-05-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OBIO Director 118,118 $6.25 $738.2K $39.9K 13 2026-06-25
LGND Director 120,580 $290.07 $34.98M -$31.81M 67 2026-06-12
LFCR Director 69,967 $4.48 $313.5K $0 3 2026-06-05
Anebulo Pharmaceuticals, Inc. (ANEB) Delisted Director — $0.36 — $0 3 2025-04-07
MERRIMACK PHARMACEUTICALS INC (MACK) Delisted 10%+ Owner 3,802 $15.13 $57.5K $21.5K 2 2019-07-18
Aralez Pharmaceuticals Inc. (ARLZ) Delisted Director 15,000 — — $1.17M 4 2017-05-24
NOVELION THERAPEUTICS INC. (NVLN) Delisted Director 369,924 — — $3.2K 2 2017-05-17
IMMUNOMEDICS INC (IMMU) Delisted Director — — — $0 1 2017-01-10
QLTI Director 535,478 $26.85 $14.38M $1.05M 18 2016-06-21
Myrexis, Inc. (MYRX) Delisted Director 9,900 — — $1.15M 19 2012-06-20
Vaxart, Inc. (NABI) Delisted Director 21,964 — — -$5.87M 39 2011-05-27

Recent Filings

177 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-25 OBIO Grant (A) — $0 EDGAR
2026-06-12 LGND Mixed −4,164 -$1.25M EDGAR
2026-06-11 LGND Notice (144) −4,500 -$1.12M EDGAR
2026-06-10 LGND Notice (144) −500 -$125.0K EDGAR
2026-06-10 LGND Notice (144) −5,000 -$1.25M EDGAR
2026-06-05 LFCR Grant (A) +25,907 $0 EDGAR
2026-05-20 OBIO Buy (P) +665 $2.5K EDGAR
2026-05-19 OBIO Buy (P) +8,971 $35.0K EDGAR
2025-12-08 LGND Exer (M) +2,034 $141.4K EDGAR
2025-09-24 LGND Sell (S) −10,000 -$1.71M EDGAR
Showing 1–10 of 177
Page 1 of 18
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.